Monte Rosa Therapeutics, Inc. (GLUE) Stock Forecast & Price Target

Monte Rosa Therapeutics, Inc. (GLUE) has an ST Score of 45.3 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate GLUE a Buy, with a price target of $24.83 (+118.6% vs the current price). Our ST Score grades it C+ (45.3/100). The ST Score is a data-driven signal, not a recommendation.

Valuation C+, Profitability B, Financial Strength B-, Momentum C-, Growth D, Forecast A.

Monte Rosa Therapeutics, Inc. (GLUE) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Monte Rosa Therapeutics, Inc. (GLUE) earns a growth grade of D, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Monte Rosa Therapeutics, Inc. (GLUE) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Monte Rosa Therapeutics, Inc. (GLUE) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Monte Rosa Therapeutics, Inc. (GLUE) is $24.83 from 10 analysts, which is +118.6% versus the recent price of $11.36.

Monte Rosa Therapeutics, Inc. (GLUE) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.